Clinical canine spinal cord injury provides an opportunity to examine the issues in translating laboratory techniques into practical therapy

Spinal Cord

Volumn 44, Issue 10, 2006, Pages 584-593

  Jeffery, N D ^a   Smith, P M ^a   Lakatos, A ^a   Ibanez, C ^a   Ito, D ^a   Franklin, R J M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Intraspinal; Naturally occurring; Translational; Transplantation

Indexed keywords

CELL TRANSPLANTATION; DISEASE MODEL; DOG DISEASE; GLIA CELL; HISTOPATHOLOGY; INCIDENCE; INJURY SCALE; LABORATORY; NONHUMAN; OLFACTORY NERVE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SPINAL CORD INJURY; TREATMENT OUTCOME; UNITED KINGDOM;

ANIMALS; CELL TRANSPLANTATION; DIFFUSION OF INNOVATION; DISEASE MODELS, ANIMAL; DOGS; HUMANS; NERVE REGENERATION; NEUROGLIA; OLFACTORY BULB; SPINAL CORD INJURIES; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 33750197486     PISSN: 13624393     EISSN: 14765624     Source Type: Journal    
DOI: 10.1038/sj.sc.3101912     Document Type: Review

References (106)

1. Curt A, Schwab ME, Dietz V. Providing the clinical basis for new interventional therapies: refined diagnosis and assessment of recovery after spinal cord injury. Spinal Cord 2004; 42: 1-6.
2. Jeffery ND, Blakemore WF. Spinal cord injury in small animals 2. Current and future options for therapy. Vet Rec 1999; 145: 183-190.
3. Kleitman N. Keeping promises: translating basic research into new spinal cord injury therapies. J Spinal Cord Med 2004; 27: 311-318.
4. Ramer LM, Ramer MS, Steeves JD. Setting the stage for functional repair of spinal cord injuries: a cast of thousands. Spinal Cord 2005; 43: 134-161.
5. Tsai EC, Tator CH. Neuroprotection and regeneration strategies for spinal cord repair. Curr Pharm Des 2005; 11: 1211-1222.
6. Kwon BK, Tetzlaff W, Grauer JN, Beiner J, Vaccaro AR. Pathophysiology and pharmacologic treatment of acute spinal cord injury. Spine J 2004; 4: 451-464.
7. Bunge MB. Bridging areas of injury in the spinal cord. Neuroscientist 2001; 7: 325-339.
8. Hendriks WT, Ruitenberg MJ, Blits B, Boer GJ, Verhaagen J. Viral vector-mediated gene transfer of neurotrophins to promote regeneration of the injured spinal cord. Prog Brain Res 2004; 146: 451-476.
9. Pearse DD et al. cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury. Nat Med 2004; 10: 610-616.
10. Reier PJ. Cellular transplantation strategies for spinal cord injury and translational neurobiology. Neurorx 2004; 1: 424-451.
11. Schwab ME. Increasing plasticity and functional recovery of the lesioned spinal cord. Prog Brain Res 2002; 137: 351-359.
12. Gomes JA, Stevens RD, Lewin III JJ, Mirski MA, Bhardwaj A. Glucocorticoid therapy in neurologic critical care. Crit Care Med 2005; 33: 1214-1224.
13. Narayan RK et al. Clinical trials in head injury. J Neurotrauma 2002; 19: 503-557.
14. Boyd JG, Doucette R, Kawaja MD. Defining the role of olfactory ensheathing cells in facilitating axon remyelination following damage to the spinal cord. FASEB J 2005; 19: 694-703.
15. Huang H et al. Influence of patients' age on functional recovery after transplantation of olfactory ensheathing cells into injured spinal cord injury. Chin Med J (England) 2003; 116: 1488-1491.
16. Rabinovich SS et al. Transplantation treatment of spinal cord injury patients. Biomed Pharmacother 2003; 57: 428-433.
17. Senior K. Olfactory ensheathing cells to be used in spinal-cord repair trial. Lancet Neurol 2002; 1: 269.
18. Allen AR. Surgery of experimental lesion of spinal cord equivalent to crush injury of fracture dislocation of spinal column. A preliminary report. J Am Med Assoc 1911; 57: 878-880.
19. Stokes BT, Jakeman LB. Experimental modelling of human spinal cord injury: a model that crosses the species barrier and mimics the spectrum of human cytopathology. Spinal Cord 2002; 40: 101-109.
20. Wrathall JR. Spinal cord injury models. J Neurotrauma 1992; 9(Suppl 1): S129-S134.
21. Young W. Spinal cord contusion models. Prog Brain Res 2002; 137: 231-255.
22. Rivlin AS, Tator CH. Effect of duration of acute spinal cord compression in a new acute cord injury model in the rat. Surg Neurol 1978; 10: 38-43.
23. Wells JE, Hurlbert RJ, Fehlings MG, Yong VW. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain 2003; 126: 1628-1637.
24. Fehlings MG, Nashmi R. A new model of acute compressive spinal cord injury in vitro. J Neurosci Methods 1997; 71: 215-224.
25. Bregman BS et al. Transplants and neurotrophic factors increase regeneration and recovery of function after spinal cord injury. Prog Brain Res 2002; 137: 257-273.
26. Ramon-Cueto A, Cordero MI, Santos-Benito FF, Avila J. Functional recovery of paraplegic rats and motor axon regeneration in their spinal cords by olfactory ensheathing glia. Neuron 2000; 25: 425-435.
27. Fouad K, Schnell L, Bunge MB, Schwab ME, Liebscher T, Pearse DD. Combining Schwann cell bridges and olfactory-ensheathing glia grafts with chondroitinase promotes locomotor recovery after complete transection of the spinal cord. J Neurosci 2005; 25: 1169-1178.
28. Bareyre FM, Kerschensteiner M, Raineteau O, Mettenleiter TC, Weinmann O, Schwab ME. The injured spinal cord spontaneously forms a new intraspinal circuit in adult rats. Nat Neurosci 2004; 7: 269-277.
29. Diener PS, Bregman BS. Fetal spinal cord transplants support growth of supraspinal and segmental projections after cervical spinal cord hemisection in the neonatal rat. J Neurosci 1998; 18: 779-793.
30. Hauben E et al. Vaccination with dendritic cells pulsed with peptides of myelin basic protein promotes functional recovery from spinal cord injury. J Neurosci 2003; 23: 8808-8819.
31. Jones TB et al. Passive or active immunization with myelin basic protein impairs neurological function and exacerbates neuropathology after spinal cord injury in rats. J Neurosci 2004; 24: 3752-3761.
32. Teng YD, Wrathall JR. Local blockade of sodium channels by tetrodotoxin ameliorates tissue loss and long-term functional deficits resulting from experimental spinal cord injury. J Neurosci 1997; 17: 4359-4366.
33. Wrathall JR, Teng YD, Choiniere D. Amelioration of functional deficits from spinal cord trauma with systemically administered NBQX, an antagonist of non-N-methyl-D-aspartate receptors. Exp Neurol 1996; 137: 119-126.
34. Noble LJ, Wrathall JR. Correlative analyses of lesion development and functional status after graded spinal cord contusive injuries in the rat. Exp Neurol 1989; 103: 34-40.
35. Martin D et al. Experimental acute traumatic injury of the adult rat spinal cord by a subdural inflatable balloon: methodology, behavioral analysis, and histopathology. J Neurosci Res 1992; 32: 539-550.
36. Vanicky I, Urdzikova L, Saganova K, Cizkova D, Galik J. A simple and reproducible model of spinal cord injury induced by epidural balloon inflation in the rat. J Neurotrauma 2001; 18: 1399-1407.
37. Fukuda S et al. New canine spinal cord injury model free from laminectomy. Brain Res Brain Res Protoc 2005; 14: 171-180.
38. Hashimoto T, Fukuda N. New spinal cord injury model produced by spinal cord compression in the rat. J Pharmacol Methods 1990; 23: 203-212.
39. al-Mefty O et al. Experimental chronic compressive cervical myelopathy. J Neurosurg 1993; 79: 550-561.
40. Maas AI. Neuroprotective agents in traumatic brain injury. Expert Opin Investig Drugs 2001; 10: 753-767.
41. Blakemore WF, Chari DM, Gilson JM, Crang AJ. Modelling large areas of demyelination in the rat reveals the potential and possible limitations of transplanted glial cells for remyelination in the CNS. Glia 2002; 38: 155-168.
42. Li Y, Field PM, Raisman G. Regeneration of adult rat corticospinal axons induced by transplanted olfactory ensheathing cells. J Neurosci 1998; 18: 10514-10524.
43. Barakat DJ et al. Survival, integration, and axon growth support of glia transplanted into the chronically contused spinal cord. Cell Transplant 2005; 14: 225-240.
44. Ramer LM, Au E, Richter MW, Liu J, Tetzlaff W, Roskams AJ. Peripheral olfactory ensheathing cells reduce scar and cavity formation and promote regeneration after spinal cord injury. J Comp Neurol 2004; 473: 1-15.
45. Brosamle C, Huber AB, Fiedler M, Skerra A, Schwab ME. Regeneration of lesioned corticospinal tract fibers in the adult rat induced by a recombinant, humanized IN-1 antibody fragment. J Neurosci 2000; 20: 8061-8068.
46. Li S et al. Blockade of Nogo-66, myelin-associated glycoprotein, and oligodendrocyte myelin glycoprotein by soluble Nogo-66 receptor promotes axonal sprouting and recovery after spinal injury. J Neurosci 2004; 24: 10511-10520.
47. GrandPre T, Li S, Strittmatter SM. Nogo-66 receptor antagonist peptide promotes axonal regeneration. Nature 2002; 417: 547-551.
48. Namiki J, Kojima A, Tator CH. Effect of brain-derived neurotrophic factor, nerve growth factor, and neurotrophin-3 on functional recovery and regeneration after spinal cord injury in adult rats. J Neurotrauma 2000; 17: 1219-1231.
49. Bradbury EJ, Khemani S, King VR, Priestley JV, McMahon SB. NT-3 promotes growth of lesioned adult rat sensory axons ascending in the dorsal columns of the spinal cord. Eur J Neurosci 1999; 11: 3873-3883.
50. Cao Q et al. Functional recovery in traumatic spinal cord injury after transplantation of multineurotrophin-expressing glial-restricted precursor cells. J Neurosci 2005; 25: 6947-6957.
51. Ruitenberg MJ, Levison DB, Lee SV, Verhaagen J, Harvey AR, Plant GW. NT-3 expression from engineered olfactory ensheathing glia promotes spinal sparing and regeneration. Brain 2005; 128: 839-853.
52. Kolata RJ, Johnston DE. Motor vehicle accidents in urban dogs: a study of 600 cases. J Am Vet Med Assoc 1975; 167: 938-941.
53. Goggin JE, Li AS, Franti CE. Canine intervertebral disk disease: characterization by age, sex, breed, and anatomic site of involvement. Am J Vet Res 1970; 31: 1687-1692.
54. Hoerlein BF. Intervertebral discs. In: Hoerlein BF (ed). Canine Neurology. 3rd Edn, Chapter 14. WB Saunders: Philadelphia 1978, pp 470-560.
55. Griffiths IR. Spinal cord injuries: a pathological study of naturally occurring lesions in the dog and cat. J Comp Pathol 1978; 88: 303-315.
56. Griffiths IR. Some aspects of the pathology and pathogenesis of the myelopathy caused by disc protrusions in the dog. J Neurol Neurosurg Psychiatry 1972; 35: 403-413.
57. Hoerlein BF. Intervertebral disc disease. In: Oliver Jr JE, Hoerlein BF, Mayhew IG (eds). Veterinary Neurology. WB Saunders: Philadelphia 1987, p 328.
58. Olby N, Harris T, Burr J, Munana K, Sharp N, Keene B. Recovery of pelvic limb function in dogs following acute intervertebral disc herniations. J Neurotrauma 2004; 21: 49-59.
59. Blight AR, Toombs JP, Bauer MS, Widmer WR. The effects of 4-aminopyridine on neurological deficits in chronic cases of traumatic spinal cord injury in dogs: a phase I clinical trial. J Neurotrauma 1991; 8: 103-119.
60. Borgens RB et al. An imposed oscillating electrical field improves the recovery of function in neurologically complete paraplegic dogs. J Neurotrauma 1999; 16: 639-657.
61. Laverty PH et al. A preliminary study of intravenous surfactants in paraplegic dogs: polymer therapy in canine clinical SCI. J Neurotrauma 2004; 21: 1767-1777.
62. Waxman SG. Demyelination in spinal cord injury. J Neurol Sci 1989; 91: 1-14.
63. Bunge RP, Puckett WR, Becerra JL, Marcillo A, Quencer RM. Observations on the pathology of human spinal cord injury. A review and classification of 22 new cases with details from a case of chronic cord compression with extensive focal demyelination. Adv Neurol 1993; 59: 75-89.
64. Guest JD, Hiester ED, Bunge RP. Demyelination and Schwann cell responses adjacent to injury epicenter cavities following chronic human spinal cord injury. Exp Neurol 2005; 192: 384-393.
65. Jones TB, McDaniel EE, Popovich PG. Inflammatory-mediated injury and repair in the traumatically injured spinal cord. Curr Pharm Des 2005; 11: 1223-1236.
66. Selcer RR, Bubb WJ, Walker TL. Management of vertebral column fractures in dogs and cats: 211 cases (1977-1985). J Am Vet Med Assoc 1991; 198: 1965-1968.
67. Coates JR. Intervertebral disk disease. Vet Clin North Am Small Anim Pract 2000; 30: 77-110.
68. Catz A, Goldin D, Fishel B, Ronen J, Bluvshtein V, Gelernter I. Recovery of neurologic function following nontraumatic spinal cord lesions in Israel. Spine 2004; 29: 2278-2282.
69. Scivoletto G, Morganti B, Ditunno P, Ditunno JF, Molinari M. Effects on age on spinal cord lesion patients' rehabilitation. Spinal Cord 2003; 41: 457-464.
70. Little JW, Ditunno Jr JF, Stiens SA, Harris RM. Incomplete spinal cord injury: neuronal mechanisms of motor recovery and hyperreflexia. Arch Phys Med Rehabil 1999; 80: 587-599.
71. Bracken MB et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the second national acute spinal cord injury study. N Engl J Med 1990; 322: 1405-1411.
72. Coleman WP et al. A critical appraisal of the reporting of the national acute spinal cord injury studies (II and III) of methylprednisolone in acute spinal cord injury. J Spinal Disord 2000; 13: 185-199.
73. Olby N, Levine J, Harris T, Munana K, Skeen T, Sharp N. Long-term functional outcome of dogs with severe injuries of the thoracolumbar spinal cord: 87 cases (1996-2001). J Am Vet Med Assoc 2003; 222: 762-769.
74. Ito D et al. Magnetic resonance imaging as a prognostic indicator in dogs with paraplegia caused by thoracolumbar intervertebral disk herniation: 77 cases (2000-2003). J Am Vet Med Assoc 2005; 227: 1454-1460.
75. Toombs JP, Waters DJ. Intervertebral disc disease. In: Slatter D (ed). Textbook of Small Animal Surgery. 3rd edn. WB Saunders: Philadelphia 2003, pp 1193-1209.
76. Kornegay JN, Marshall AE, Purinton PT, Oliver Jr JE. Somatosensory-evoked potential in clinically normal dogs. Am J Vet Res 1981; 42: 70-73.
77. Sylvestre AM, Cockshutt JR, Parent JM, Brooke JD, Holmberg DL, Partlow GD. Magnetic motor evoked potentials for assessing spinal cord integrity in dogs with intervertebral disc disease. Vet Surg 1993; 22: 5-10.
78. Vanderzant CW, Schott RJ, Natale JE, Pondo CA, D'Alecy LG. Somatosensory evoked potentials of the dog: recording techniques and normal values. J Neurosci Methods 1989; 27: 253-263.
79. Poncelet L, Michaux C, Balligand M. Somatosensory potentials in dogs with naturally acquired thoracolumbar spinal cord disease. Am J Vet Res 1993; 54: 1935-1941.
80. Olby NJ et al. Development of a functional scoring system in dogs with acute spinal cord injuries. Am J Vet Res 2001; 62: 1624-1628.
81. Webb AA, Jeffery ND, Olby NJ, Muir GD. Behavioural analysis of the efficacy of treatments for injuries to the spinal cord in animals. Vet Rec 2004; 155: 225-230.
82. Lane IF. Diagnosis and management of urinary retention. Vet Clin N Am 2000; 30: 25-57.
83. Abdel-Gawad M, Boyer S, Sawan M, Elhilali MM. Reduction of bladder outlet resistance by selective stimulation of the ventral sacral root using high frequency blockade: a chronic study in spinal cord transected dogs. J Urol 2001; 166: 728-733.
84. Gregory SP, Holt PE. Comparison of stressed simultaneous urethral pressure profiles between anesthetized continent and incontinent bitches with urethral sphincter mechanism incompetence. Am J Vet Res 1993; 54: 216-222.
85. Drew T, Jiang W, Widajewicz W. Contributions of the motor cortex to the control of the hindlimbs during locomotion in the cat. Brain Res Brain Res Rev 2002; 40: 178-191.
86. Starkey ML et al. Assessing behavioural function following a pyramidotomy lesion of the corticospinal tract in adult mice. Exp Neurol 2005; 195: 524-539.
87. Dietz V. Do human bipeds use quadrupedal coordination? Trends Neurosci 2002; 25: 462-467.
88. Westgren N, Levi R. Quality of life and traumatic spinal cord injury. Arch Phys Med Rehabil 1998; 79: 1433-1439.
89. Anderson KD. Targeting recovery: priorities of the spinal cord-injured population. J Neurotrauma 2004; 21: 1371-1383.
90. Hofstetter CP et al. Allodynia limits the usefulness of intraspinal neural stem cell grafts; directed differentiation improves outcome. Nat Neurosci 2005; 8: 346-353.
91. Scott HW, McKee WM. Laminectomy for 34 dogs with thoracolumbar intervertebral disc disease and loss of deep pain perception. J Small Anim Pract 1999; 40: 417-422.
92. Jones SR, Carley S, Harrison M. An introduction to power and sample size estimation. Emerg Med J 2003; 20: 453-458.
93. Hathaway D, Winsett R, Prendergast M, Subaiya I. The first report from the patient outcomes registry for transplant effects on life (PORTEL): differences in side-effects and quality of life by organ type, time since transplant and immunosuppressive regimens. Clin Transplant 2003; 17: 183-194.
94. Barnett SC, Roskams AJ. Olfactory ensheathing cells. Isolation and culture from the rat olfactory bulb. Methods Mol Biol 2002; 198: 41-48.
95. Riddell JS, Enriquez-Denton M, Toft A, Fairless R, Barnett SC. Olfactory ensheathing cell grafts have minimal influence on regeneration at the dorsal root entry zone following rhizotomy. Glia 2004; 47: 150-167.
96. Lu J, Feron F, Mackay-Sim A, Waite PM. Olfactory ensheathing cells promote locomotor recovery after delayed transplantation into transected spinal cord. Brain 2002; 125: 14-21.
97. Ramer LM, Au E, Richter MW, Liu J, Tetzlaff W, Roskams AJ. Peripheral olfactory ensheathing cells reduce scar and cavity formation and promote regeneration after spinal cord injury. J Comp Neurol 2004; 473: 1-15.
98. Feron F et al. Autologous olfactory ensheathing cell transplantation in human spinal cord injury. Brain 2005; 128: 2951-2960.
99. Smith PM, Lakatos A, Barnett SC, Jeffery ND, Franklin RJM. Cryopreserved cells isolated from the adult canine olfactory bulb are capable of extensive remyelination following transplantation into the adult rat CNS. Exp Neurol 2002; 176: 402-406.
100. Jeffery ND, Lakatos A, Franklin RJM. Autologous olfactory glial cell transplantation is reliable and safe in naturally-occurring canine spinal cord injury. J Neurotrauma 2005; 22: 1282-1293.
101. Fawcett JW, Asher RA. The glial scar and central nervous system repair. Brain Res Bull 1999; 49: 377-391.
102. Lakatos A, Barnett SC, Franklin RJM. Olfactory ensheathing cells induce less host astrocyte response and chondroitin sulphate proteoglycan expression than Schwann cells following transplantation into adult CNS white matter. Exp Neurol 2003; 184: 237-246.
103. Raisman G. Olfactory ensheathing cells - another miracle cure for spinal cord injury? Nat Rev Neurosci 2001; 2: 369-375.
104. Kulbatski I, Mothe AJ, Nomura H, Tator CH. Endogenous and exogenous CNS derived stem/progenitor cell approaches for neurotrauma. Curr Drug Targets 2005; 6: 111-126.
105. Bradbury EJ et al. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature 2002; 416: 636-640.
106. Nikulina E, Tidwell JL, Dai HN, Bregman BS, Filbin MT. The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery. Proc Natl Acad Sci USA 2004; 101: 8786-8790.